Clinical trial registry record

A Depot Formulation of Sunitinib Malate (GB-102) Compared to Aflibercept in Subjects With Wet AMD

A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Completed.
Evidence
Registered phase 2 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated January 19, 2022.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT03953079
Last registry update
January 19, 2022
Status
Completed
Phase
Phase 2
Sponsor
Graybug Vision
Enrollment
56
Countries
United States
Match confidence
60%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 2
Study design
RANDOMIZED · PARALLEL · TREATMENT · SINGLE
Evidence population
Human clinical study registration
Participants
56
Population
ALL · 50 Years
Duration
2019-09-26 to 2021-06-03
Intervention
Drug: GB-102; Aflibercept
Comparator
Aflibercept 2 mg
Outcomes measured
Time to First Rescue Treatment — Baseline through 12 months; Time to Fulfillment of at Least One Rescue Criterion — 6 months through 12 months; Number of Times That at Least One Rescue Criterion is Met — Baseline through 12 months; Number of Treatments, Including Both Rescue and Scheduled Study Treatments, During the Study — Baseline through 12 mont…; Change From Baseline in Best-corrected Visual Acuity (BCVA) (ETDRS Letter Score) at All Visits — Baseline through 12 mo…; Categorical Change From Baseline in BCVA (ETDRS Letter Score) at All Visits — Baseline through 12 months; Frequency of Subjects With BCVA Worse Than 20/200 (Snellen Equivalent) at All Visits — Baseline through 12 months; Change From Baseline in Central Subfield Thickness (CST) (μm) at All Visits — Baseline through 12 months; Frequency of Subjects With Absence of Exudation (Intra-/Sub-retinal Fluid/Cystoid Edema) at at All Visits — Baseline th…
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 2A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 60% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Vision ageing · 60%Source terminology contains: age-related macular degeneration. Source terminology supplies longevity context: age-related. Study type is explicitly identified as INTERVENTIONAL.

Automated source check 100% · update recency 50%. These figures help sort records; they are not medical ratings.

vision aging
Open primary sourceExport JSON